ATX 1.47% 6.7¢ amplia therapeutics limited

Ann: Quarterly Activities and Cashflow Reports - Dec 2020 Qtr, page-10

  1. 2,130 Posts.
    lightbulb Created with Sketch. 667
    Nice foxy43 ... lots of good stuff in here

    Getting to phase one clinical trials gives investors a confidence boost. So does the fact that Amplia secured two orphan drug designations for AMP945 from the US Food and Drug Administration.

    With these in hand, the company qualifies for reduced fees from the regulator, help with clinical trials and market exclusivity should its drug cross the finish line.

    More broadly, there’s growing interest in this approach to fighting cancers and in the science emerging from Australian laboratories.

    Two drug programmes developed by Cancer Therapeutics CRC have been licensed to global pharmaceutical companies, including Pfizer, in deals worth nearly US$1bn.


    In deals worth nearly US$1bn ...


    From ...

    John Lambert

    Chief Executive Officer at Amplia Therapeutics Limited



    “A really nice article backgrounding the origins of Amplia Therapeutics, our founders and the value of persistence and tenacity. We're proud to be advancing such high quality Australian science into clinical trials and towards the patients who we hope will benefit from our work.”



    https://www.mewburn.com/news-insigh...945?utm_campaign=Pharma&utm_source=damian
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
(20min delay)
Last
6.7¢
Change
-0.001(1.47%)
Mkt cap ! $18.19M
Open High Low Value Volume
6.7¢ 7.0¢ 6.7¢ $95 1.411K

Buyers (Bids)

No. Vol. Price($)
1 12728 6.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.0¢ 21327 1
View Market Depth
Last trade - 15.59pm 14/06/2024 (20 minute delay) ?
Last
6.9¢
  Change
-0.001 ( 1.47 %)
Open High Low Volume
6.7¢ 6.9¢ 6.7¢ 333
Last updated 15.48pm 14/06/2024 ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.